Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Dollar Steady as Markets Await U.S. Inflation Data 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Add as a preferred source on Google
Roche Diagnostics Korea revealed on Thursday, May 6, that it was granted approval for its Cobas test, a testing device used to detect severe acute respiratory syndrome coronavirus in laboratories.
Roche Diagnostic’s Cobas test - What it is
The Korea Herald reported that Roche Diagnostics Korea said that its Cobas test is not only effective in qualitative detection, but it can also differentiate between SARS-CoV-2, Influenza A, and Influenza B that may be present in nasal swab samples from individuals undergoing test for possible respiratory infection.
It was added that Roche’s Cobas SARS-CoV-2 test could also be utilized in the company’s automated molecular testing solutions, called the cobas 6800/8800 Systems. This has the capacity to furnish up to 96 results in as little as three hours, while the cobas 8800 System can give 960 results within eight hours.
Moreover, Roche’s cobas SARS-CoV-2 test boasts of more than 97% test sensitivity, thus allowing a more accurate identification if a virus is present or not. The company added that this can deliver results fast and accurately so that doctors can give the right diagnosis and prescribe the right treatment for the case.
Roche increased investment in S. Korea
Meanwhile, Roche Diagnostics AG is headquartered in Basel, Switzerland, and because it saw how South Korea responded to the COVID-19 pandemic, the company said it is investing more in Roche Korea due to its excellent response to the crisis.
“Compared to other countries, Korea has been controlling Covid-19 well,” Korea BioMed Review quoted Roche Diagnostics Korea’s general manager, Johnny Tse, as saying. “But it needs to prepare for the next stage. Most Covid-19 tests use PCR (polymerase chain reaction) but we may need antibody/antigen tests, rapid testing for crossing borders, or tests based on the progress of the disease (Covid-19).”
Roche made the right decision to invest more since the cobas SARS-CoV-2 test has finally been approved after efforts were exerted to produce this device that will help detect COVID-19 more accurately. Finally, Tse said that they are planning to continue investing in S. Korea and create more of the things that are needed in helping curb highly infectious diseases.
